← All trials
NCT06337630
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 15, 2024
- Primary completion
- Jun 15, 2025
- Completion date
- Feb 15, 2029
- First posted
- Mar 29, 2024
- Last posted
- Mar 29, 2024
- Enrollment
- 92
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Curie InstituteLead sponsor
- MerckCollaborator
- ProLynx LLCCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.